Document:

<PAGE>
                                                                    EXHIBIT 10.2

                              FORBEARANCE AGREEMENT

         This Forbearance Agreement ("Agreement"), dated as September 30, 2001,
is between U.S. Bank National Association (the "Bank") and Geographics, Inc.
(the "Borrower").

                                    RECITALS

         A. Bank and Borrower are parties to a Loan and Security Agreement dated
December 22, 1999, as amended by the First Amendment to Loan and Security
Agreement dated April 17, 2000 and the Second Amendment to Loan and Security
Agreement dated as of June 30, 2001 (as amended, the "Loan Agreement").

         B. Borrower acknowledges that defaults ("Forbearance Defaults") exist
under the Loan Agreement and Bank is entitled to exercise its rights and
remedies under the Loan Agreement, including, but not limited to, ceasing to
make advances and realizing on the Collateral.

         C. Borrower has indicated that it is negotiating with another party to
either sell its business and assets or merge with another entity, and Borrower
has requested that Bank forbear until January 31, 2002 to allow Borrower to
complete either a sale or merger.

         D. Borrower has agreed that on or before January 31, 2002 it will
either (i) accomplish the sale of its business and assets and pay the Bank in
full or (ii) merge with another entity and provide Bank with a commitment for
new financing in order to pay all amounts owing to the Bank in full.

         E. Borrower acknowledges that the Bank does not agree to continue to
provide financing to Borrower beyond January 31, 2002.

         F. Borrower further acknowledges that the Bank has not consented to a
merger, and will not provide such consent unless the terms of such merger are
acceptable to the Bank and the Borrower has a commitment for new financing with
a reasonable expectation of promptly closing on such financing and paying all
amounts owing to the Bank in full.

         G. Bank is willing to enter into this Agreement and forbear exercise of
remedies until January 31, 2002, solely to allow Borrower time to either
finalize its agreement for sale of its business and assets or merge with another
entity and pay Bank in full, under the terms and conditions contained herein,
provided that (i) except as expressly provided herein, Bank does not waive any
Events of Default, and (ii) Bank does not agree to finance Borrower beyond
January 31, 2002.

<PAGE>

                                    AGREEMENT

         NOW, THEREFORE, the Bank and Borrower hereby agree as follows:

         1. Definitions.

                  (a) Capitalized terms used but not defined herein shall have
the meanings ascribed to such terms in this Loan Agreement.

                  (b) Effective as December 18, 2001, "Adjusted LIBOR Rate"
means with respect to an Interest Period for a LIBOR Rate Loan, a rate per annum
(rounded upward, if necessary, to the nearest 1/16 of 1%) determined pursuant to
the following formula: Adjusted LIBOR Rate = [LIBOR Rate / (1 - LIBOR Reserve
Requirement)] + 3.0%.

                  (c) Effective as of September 30, 2001, "Real Estate Sublimit"
shall mean $1,750,000.00.

         2. Term and Termination. Section 10 of the Loan Agreement is hereby
amended to delete "September 30, 2001" and replace it with "January 31, 2002".

         3. Subordinated Debt and Security Interest. Bank hereby consents to
Borrower's subordinated debt of $500,000.00 to Jonathan S. Miner, which debt
shall be unsecured ("Miner Debt") Borrower may not repay any portion of the
Miner Debt without the prior written consent of the Bank.

         4. Agreement for Sale or Merger. On or before January 2, 2002, Borrower
shall furnish to Bank either (a) a fully executed purchase agreement for the
sale of Borrower's business and assets, in form and content satisfactory to
Bank, with a closing scheduled no later than January 31, 2002, or (b) evidence
satisfactory to Bank that Borrower has agreed upon a plan of merger with another
entity to be completed no later than January 31, 2002. Borrower acknowledges
that if Borrower presents the Bank with a plan of merger, the Bank may not
consent to such merger unless the terms and conditions of such merger are
acceptable to Bank, and Borrower, on or before January 31, 2002, obtains a
commitment for new financing which will pay all amounts owing to the Bank in
full.

         5. Completion of Sale or Merger. On or before January 31, 2002,
Borrower shall either (a) complete the sale of its business and assets, and pay
all amounts owing to the Bank in full, or (b) merge with another entity, on
terms and conditions acceptable to Bank, in addition to providing Bank with a
commitment for new financing which will pay all amounts owing to the Bank in
full.

         6. Forbearance Defaults; No Waiver. The Forbearance Defaults are
material and include defaults under financial and other covenants. Bank has
agreed that, subject to the terms hereof, notwithstanding the Forbearance
Defaults, Bank will continue to advance funds under the

                                      -2-
<PAGE>

Revolving Credit Facility, provided that Bank shall not at any time be required
to advance any amount in excess of the amount permitted to be advanced under
Section 4 of the Loan Agreement as amended hereby. The Bank does not waive any
Events of Default. The Bank's agreement to forbear under this Forbearance
Agreement shall terminate on the earliest to occur of the following (each a
"Termination Event"): (a) January 31, 2002 or (b) the occurrence of, or the
Bank's obtaining knowledge of, any Event of Default (other than a Forbearance
Default), or an increase in scope or magnitude of a Forbearance Default (in each
of the cases described in this clause (b), an "Additional Default"). Borrower
expressly acknowledges that subject to the terms of the Loan Agreement as
amended hereby, Bank has agreed to forbear exercising their rights and remedies
until January 31, 2002, but in any event, Bank has not agreed to, and is not
obligated to, continue to provide financing to Borrower beyond such date.

         7. Conditions to Effectiveness of this Agreement. This Amendment shall
not be effective until this Amendment shall have been fully executed and
delivered to Bank and Bank shall have received the following in form and
substance satisfactory to Bank:

                  (a) Corporate Resolutions of Borrower authorizing this
Amendment accompanied by an Officer's Certificate signed by an officer of
Borrower.

         8. Effective of Agreement. Except as amended hereby, the Loan Agreement
shall remain in full force and effect.

         9. Attorneys' Fees. The Borrower agrees to pay all reasonable
attorneys' fees of Bank relating to this Agreement and all amendments,
modifications and supplements hereto.

         10. Law Governing. This Agreement shall be governed by the laws of the
State of Wisconsin.

         11. Binding Effect. This Agreement shall be binding upon the parties
hereto and their respective successors and assigns.

         12. Release of Bank. In consideration of the accommodations by Bank
hereunder, Borrower does hereby, on behalf of itself, its agents, insurers,
successors and assigns, release, acquit and forever discharge Bank and Bank's
affiliates, together with all of their present and former directors, officers,
agents and employees, from any and all claims, demand or causes of action of any
kind, nature or description whether arising in law or equity or upon contract or
tort or under any state or federal law or otherwise, which Borrower has had, now
has or has made claim to have against any such party or by reason of any act,
omission, matter, cause or thing whatsoever from the beginning of time to and
including the date of this Agreement, whether such claims, demands and causes of
action are matured or unmatured or know or unknown, except Bank's executory
obligations under the Loan Agreement as hereby amended. Notwithstanding the
foregoing, nothing herein shall be construed as a release of Bank's liability
for gross negligence or willful misconduct.

                                      -3-
<PAGE>

         The parties hereto have executed this Agreement on the day and year
first above written.

BORROWER:                                   BANK:
Geographics, Inc.                           U.S. Bank National Association

By:   /s/ James L. Dorman                   By:    /s/ Dennis J. Ciche
   --------------------------------            ---------------------------------
   James L. Dorman, Chief Executive Officer    Dennis J. Ciche, Vice President

                                      -4-<PAGE>
                                                                     Exhibit 4.3

                     BAYER CORPORATION SHARE INCENTIVE PLAN

1.       Introduction

         Bayer Aktiengesellschaft ("Bayer AG") offers certain management
         employees of Bayer AG and selected German subsidiaries participation in
         its stock option plan for 2001 (the "Bayer AG Plan"). The Bayer
         Corporation Share Incentive Plan, which is intended to be substantially
         the same as the Bayer AG Plan, will be offered to certain management
         employees of Bayer Corporation and certain of its U.S. subsidiaries
         beginning in 2002.

2.       Requirements for Participation

         (a)      Employees who are eligible to participate will be notified of
                  their eligibility by Bayer Corporation.

         (b)      Qualification for plan participation includes a personal
                  investment by the participant as condition precedent. Each
                  participant must make a deposit of a specified amount of Bayer
                  AG American Depositary Shares ("Bayer ADSs") with the
                  custodian as a condition precedent to taking part in the plan.
                  The participants may purchase the Bayer ADSs themselves on the
                  market and/or may deposit already owned shares not pledged or
                  otherwise encumbered. The minimum and maximum number of Bayer
                  ADSs that a participant may invest in the plan will be
                  determined by Bayer Corporation. The minimum and maximum
                  number of Bayer ADSs that a participant must invest to
                  participate in the plan may be adjusted in the event of
                  changes in the capital structure of Bayer AG.

         (c)      Bayer Corporation must be informed in writing of participation
                  in the plan by the date established by Bayer Corporation, and
                  the Bayer ADSs must be deposited with the custodian beginning
                  on, and continuing up until, the dates established under the
                  Bayer AG Plan for that Award Cycle (the "Holding Period").
                  During the Holding Period, the deposited Bayer ADSs cannot be
                  sold, encumbered, or otherwise transferred.

3.       Grant of Warrants

         Every participant who meets the above requirements receives warrant
         rights ("Warrants") for Bayer ADSs based on the outstanding amount of
         730,341,920 ordinary shares of Bayer AG (the "Bayer AG Stock") as of
         December 31, 2000.

         For every 20 Bayer ADSs deposited by a participant under the plan, the
         participant will receive one Warrant. The number of total shares of
         Bayer ADSs deposited must be divisible by 20.

                                     - 1 -
<PAGE>

4.       Rights of the Warrants

         Each Warrant represents a right upon exercise to receive a certain
         number of incentive Bayer ADSs. The number of Bayer ADSs to be received
         for each Warrant is based on the stock market performance of the Bayer
         AG Stock.

5.       Determination of Success Criteria

         5.1      Performance Criteria

                  The share performance is judged on one hand based upon the
                  Performance of Bayer AG Stock and on the other hand based upon
                  the Outperformance of the Bayer AG Stock compared to the Dow
                  Jones EURO STOXX 50(SM) (performance index). At least one of
                  the two performance criteria must be achieved to exercise
                  Warrants.

         5.1.1    Determination of Stock Performance

                  For calculation purposes:

                  (a)      Each 3% of Performance of the Bayer AG Stock
                           generates a right to receive one Bayer ADS per
                           Warrant subject to a minimum performance of 30%. This
                           minimum performance hurdle must be achieved or
                           exceeded at the time the Warrants are exercised to
                           receive any incentive Bayer ADSs under this
                           Performance measure.

                  (b)      Each Outperformance of the Bayer AG Stock by 1%
                           generates a right to receive one Bayer ADS per
                           Warrant without a minimum Outperformance requirement.

                  (c)      Percent values of the Bayer Performance and/or
                           Outperformance will not be rounded up.

         5.1.2    Limitations

                  The maximum number of Bayer ADSs for each Warrant that can be
                  received for each of the criteria is limited to 50. A
                  combination of both criteria may result in no more than 100
                  shares earned for each Warrant.

         5.1.3    Performance Definition

                  The Performance of the Bayer AG Stock represents the total
                  return of the Bayer AG Stock in a given time period. Thus, in
                  addition to the share price increase and dividends paid,
                  subscription rights or other changes in the capital structure
                  (e.g., stock splits and issuance of new shares) must be taken
                  into account in the performance calculation in the suitable
                  manner to adequately reflect their value.

                                     - 2 -
<PAGE>

                  This is accomplished through the same specific mathematical
                  formulas used for the Bayer AG Plan and more closely described
                  therein. Bayer AG may revise such mathematical formulas for
                  any future Award Cycles. The following key principles are part
                  of the calculation:

                  (a)      The starting point for the calculation of performance
                           is always the beginning of the respective Award
                           Cycle.

                  (b)      The whole time period from the starting point to the
                           present is subdivided into several time intervals in
                           such a manner that only one single event, such as a
                           dividend payment or other capital measure, occurs in
                           each such time interval.

                  (c)      For each time interval the respective percentage
                           change of the value of the Bayer AG Stock (including
                           the respective value of a dividend or capital
                           measure) is computed.

                  (d)      The individual percentage gains are then compounded
                           from the beginning of the Award Cycle to the present.

         5.1.4    Definition of Outperformance

                  The Outperformance of the Bayer AG Stock is defined as the
                  difference between the total Performance of the Bayer AG Stock
                  (as calculated under Section 5.1.3 above) and the performance
                  of the Dow Jones EURO STOXX 50(SM) (performance index) during
                  the same specified time period.

         5.1.5    Definition of the Reference Price

                  The Reference Price for shares of the Bayer AG Stock is
                  calculated for each relevant time period as the average of the
                  final auction of the Xetra-Handel at the Frankfurt Stock
                  Exchange over the last 10 trading days. For the Dow Jones EURO
                  STOXX 50(SM), the definition of the Reference Rate during the
                  specified time period will be the average over the same last
                  10 trading days.

                  Other comparable sources will be used in case the respective
                  prices or indices should not be available for calculating the
                  reference rate.

         5.1.6    Dilution Protection

                  The value of the Bayer ADSs receivable for each Warrant can be
                  diluted through capital changes. Therefore, the number of
                  Bayer ADSs receivable both for the Performance and the
                  Outperformance criteria, as well as the limitation according
                  to Section 5.1.2, will be adjusted to negate the dilution.

                                     - 3 -
<PAGE>

6.       Warrant Disposition Rights

         The Warrants may not be pledged, alienated, assigned or otherwise
         transferred and may be exercised, during the participant's lifetime,
         only by the participant; provided, however, that upon a participant's
         death and during the relevant Exercise Period, a participant's
         Beneficiary may exercise the Warrants.

         In order to comply with insider trading rules related to information
         that may arise during certain times, no exercise of Warrants will be
         permitted until such insider information is externally reported (for
         example, through stockholders' meetings, press conferences or formal
         quarterly reporting). The restricted time periods, also referred to as
         blackout periods, will be timely disclosed to participants.
         Irrespective of this communication, it is the sole responsibility of
         the participant to comply with all applicable insider trading rules.
         Bayer AG, Bayer Corporation and Bayer Corporation's participating U.S.
         subsidiaries assume no liability for insider trading violations of a
         participant.

         The Warrants must be exercised in accordance with procedures
         established by Bayer Corporation in a minimum of blocks of five, unless
         there are less than five Warrants remaining. The participant or, in the
         event of the participant's death, the participant's Beneficiary, must
         provide Bayer Corporation with written notice of his/her exercise of
         Warrants by submitting a special exercise form to be made available by
         Bayer Corporation.

         The Bayer ADSs to be received through exercise of the Warrants will be
         delivered to the participant or, in the event of the participant's
         death, the participant's Beneficiary, pursuant to the instructions on
         the exercise form.

7.       Duration of Award Cycle and Holding Time

         Each individual cycle of the plan ("Award Cycle") has a duration of
         five years, composed of a three-year Holding Period and a two-year
         Exercise Period. The Holding Period and Exercise Period for each Award
         Cycle will be determined under the Bayer AG Plan and communicated to
         eligible employees by Bayer Corporation.

         Warrants may only be exercised after the Holding Period has expired and
         within the Exercise Period, subject to any blackout periods also
         outside of any Holding Period according to Section 6 above.

         In the event Warrants are not exercised by the last day of the Exercise
         Period, they will be forfeited.

         At the end of the respective Holding Period, each participant's
         personal investment originally deposited as a condition for
         participating in the plan will be released.

         A participant will receive any dividends paid on Bayer ADSs deposited
         by that participant under the plan.

                                     - 4 -
<PAGE>

8.       Specific Rules for Change of Employment

         In the event that the active employment of the participant is
         terminated (i) by Bayer Corporation or any subsidiary or affiliate of
         Bayer Corporation for a reason, determined by Bayer Corporation in its
         sole discretion, that relates to the business of Bayer Corporation or
         its subsidiaries or affiliates or that relates to the sale of all or
         any part of such business or (ii) by the participant based on the
         participant's "Disability," defined as receipt of long-term disability
         benefits under an employer-provided disability plan, or "Retirement,"
         defined as the voluntary termination of employment after the
         participant attains age 55 and completes 10 years of service, then the
         participant will maintain his or her Warrants and may exercise those
         rights at any time during the relevant Exercise Period. Alternatively,
         if the employment of the participant is terminated for any such reason
         during the Holding Period, the participant may elect to withdraw all
         (but not part) of his or her pledged Bayer ADSs and forfeit his or her
         Warrants.

         In the event that the active employment of the participant is
         terminated (i) by Bayer Corporation or any subsidiary or affiliate of
         Bayer Corporation, for any reason that is determined by Bayer
         Corporation, in its sole discretion, not to be business related or not
         for cause, or (ii) by the participant, for any other reason than death,
         Disability or Retirement, and such termination occurs during the
         relevant Holding Period, then the Warrants will be forfeited and
         pledged shares will be returned. However, if such a termination occurs
         during the relevant Exercise Period, then the participant may exercise
         the Warrants within thirty (30) days after such termination.
         Thereafter, the Warrants may no longer be exercised and will be
         forfeited.

         In the event that the active employment of the participant is
         terminated by Bayer Corporation or any subsidiary or affiliate of Bayer
         Corporation for any reason that Bayer Corporation, in its sole
         discretion, determines to be for cause, then all Warrants will,
         effective as of the moment of termination, no longer be exercisable and
         will be forfeited.

         In the event that the participant dies while in active employment or
         following Disability or Retirement, unexercised Warrants may be
         exercised by the participant's Beneficiary at any time during the
         relevant Exercise Period. Alternatively, in the event that the
         participant dies while in active employment or following Disability or
         Retirement during the Holding Period, the participant's Beneficiary may
         elect to withdraw all (but not part) of the pledged Bayer ADSs and
         forfeit the Warrants.

         Each participant may designate, on a form provided for that purpose by
         Bayer Corporation, a Beneficiary or Beneficiaries to receive his or her
         interest in the Warrants in the event of his or her death, but such
         designation shall not be effective for any purpose until it has been
         filed by him or her during his or her lifetime with Bayer Corporation.
         The participant may, from time to time during his or her lifetime, on a
         form approved by and filed with Bayer Corporation, change his or her
         Beneficiary or Beneficiaries. In the event a participant fails to
         designate a Beneficiary, the designated

                                     - 5 -
<PAGE>

         Beneficiary fails to survive the participant, or if such designation is
         legally ineffective, the Beneficiary shall be the participant's estate.

9.       Cash Settlement-Reservation

         Bayer Corporation in consultation with Bayer AG is authorized to
         satisfy any exercise of Warrants under this plan through a cash
         settlement. The amount of the cash settlement shall be determined by
         the number of shares of Bayer ADSs receivable under the Warrants
         exercised by the participant multiplied by the closing trading price of
         the Bayer ADSs on the day the Warrants are exercised, as reported by
         the New York Stock Exchange.

10.      Tax Treatment

         The participant's restricted shares from his/her personal initial
         investment remain the personal property of the participant. The
         participant is responsible for paying taxes on any dividends or other
         earnings.

         Bayer ADSs received through the exercise of Warrants or any respective
         cash settlement represent taxable income to the participant at the time
         the Warrants are exercised. The participant is responsible for payment
         of the resulting taxes. Bayer Corporation is responsible for collection
         of the resulting taxes and the appropriate reporting of the resulting
         income.

11.      Other Points

         Depending on the experience with this plan, Bayer Corporation will be
         considering new Award Cycles of this plan each year. The decision to
         offer new Award Cycles, as well as the structure and the restrictions
         on participation, remain at the sole discretion of Bayer Corporation.

         The observance of the blackout periods (as described in Section 6) in
         connection with insider information does not relieve the participant of
         his/her duty to observe all laws and other restrictions regarding
         insider trading. These restrictions also apply to all other trades of
         Bayer ADSs as a personal investment.

         To administer the plan, the participants must allow the custodian to
         provide necessary bank account and deposit information including, as
         well as verification of, personal investments and any exercise of
         Warrants to Bayer Corporation and its affiliates.

12.      Voting and Tendering of Bayer ADSs

         With respect to Bayer ADSs delivered to a participant under the plan, a
         participant (or in the event of his death, his Beneficiary or estate)
         shall have the right to instruct the custodian as to the manner in
         which to (1) exercise voting rights at each annual and each special
         meeting of the stockholders of Bayer AG, and/or (2) respond to a
         voluntary tender

                                     - 6 -
<PAGE>

         or exchange offer with respect to Bayer ADSs credited to such
         participant's account under the plan. Bayer Corporation shall utilize
         its best efforts to distribute on a timely basis or cause to be
         distributed to each participant (or Beneficiary or estate) such
         information as will be distributed to holders of the Bayer ADSs in
         connection with any such meeting or voluntary tender or exchange offer,
         together with an appropriate form for the participant to indicate his
         instructions. Upon its receipt of such instructions, the custodian
         shall cause the voting or tender of such Bayer ADSs as and to the
         extent so instructed. It is the intent of this provision of the plan to
         treat all such participants (or their Beneficiaries or their estates)
         as if they held directly all Bayer ADSs delivered to them under the
         plan so that if a participant (or Beneficiary or estate) does not
         instruct the custodian to vote, tender or exchange such Bayer ADSs at a
         stockholder meeting or pursuant to the terms of any voluntary tender or
         exchange offer, the custodian shall conclude that such participant does
         not wish to have his Bayer ADSs voted, tendered or exchanged. The
         custodian shall have no discretion in such matter and shall take no
         action with respect to any such meeting, or voluntary tender or
         exchange offer except to the extent it receives instructions from
         participants. The custodian shall keep confidential all instructions it
         receives pursuant to this Section 12, except the aggregate number of
         votes voting for or against or abstaining with respect to a matter
         submitted to a stockholder vote.

13.      Plan Administration

         Bayer Corporation shall be responsible for the administration of the
         plan. Bayer Corporation shall have all such powers as may be necessary
         to carry out the provisions hereof and may, from time to time,
         establish rules for the administration of the plan and the transaction
         of the plan's business. In making any such determination or rule, Bayer
         Corporation shall pursue uniform policies as are from time to time
         established by it and shall not discriminate in favor of or against any
         participant. Bayer Corporation shall have the exclusive right to make
         any finding of fact necessary or appropriate for any purpose under the
         plan including, but not limited to, the determination of the
         eligibility for and the amount of any benefit payable under the plan.
         Bayer Corporation shall have the exclusive discretionary right to
         interpret the terms and provisions of the plan and to determine any and
         all questions arising under the plan or in connection with the
         administration thereof, including, without limitation, the right to
         remedy or resolve possible ambiguities, inconsistencies, or omissions,
         by general rule or particular decision. All findings of fact,
         determinations, interpretations, and decisions of Bayer Corporation or
         its delegee shall be conclusive and binding upon all persons having or
         claiming to have any interest or right under the plan.

         Bayer Corporation does hereby reserve the right to amend, modify,
         suspend or terminate the plan at any time. The plan may be amended by
         the action of the Compensation Committee of the Board of Directors of
         Bayer Corporation which shall be evidenced in writing. The Compensation
         Committee may delegate this authority to such individuals or committees
         as the Compensation Committee deems appropriate.

                                     - 7 -
<PAGE>

         While Bayer Corporation contemplates carrying out the provisions of the
         plan indefinitely with respect to its employees, Bayer Corporation
         shall not be under any obligation or liability whatsoever to maintain
         the plan for any minimum or other period of time except with respect to
         any Award Cycle commenced prior to termination of the plan.

                                     - 8 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00034-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00034-of-00352.parquet"}]]